RALEIGH, N.C., April 10, 2009 (GLOBE NEWSWIRE) -- DARA Biosciences, Inc. (Nasdaq:DARA) (“DARA” or the “Company”), a development-stage pharmaceutical company, announced today that the audit report accompanying the financial statements for the fiscal year ended December 31, 2008, as included in the Company’s Annual Report on 10 -K filed on March 31, 2009, contained a going concern qualification. NASDAQ Marketplace Rule 4350(b)(1)(B) requires that a public announcement be made regarding the receipt of an audit opinion that contains a going concern qualification.
